Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. NovoCure's cash to debt ratio for the quarter that ended in Mar. 2023 was 1.63.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, NovoCure could pay off its debt using the cash in hand for the quarter that ended in Mar. 2023.
The historical rank and industry rank for NovoCure's Cash-to-Debt or its related term are showing as below:
NVCR'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.45 Med: 1.9 Max: No Debt
Current: 1.63
During the past 10 years, NovoCure's highest Cash to Debt Ratio was No Debt. The lowest was 1.45. And the median was 1.90.
NVCR's Cash-to-Debt is ranked worse than 57.56% of 860
companies
in the Medical Devices & Instruments industry
Industry Median: 2.52
vs NVCR: 1.63
NovoCure Cash-to-Debt Historical Data
The historical data trend for NovoCure's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
NovoCure Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Cash-to-Debt
1.65
1.99
1.90
1.63
1.66
NovoCure Quarterly Data
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Cash-to-Debt
1.61
1.64
1.67
1.66
1.63
Competitive Comparison
For the Medical Devices subindustry, NovoCure's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovoCure Cash-to-Debt Distribution
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where NovoCure's Cash-to-Debt falls in comparison to its industry or sector. The grey bar indicates the Cash-to-Debt's extreme value range as defined by GuruFocus.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovoCure (NAS:NVCR) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
NovoCure Cash-to-Debt Related Terms
Thank you for viewing the detailed overview of NovoCure's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.
Create New Portfolio
Portfolio Contest
Personalize
Premium Gurus 
35.51(43.04%) Volume: 12,276,042 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NVCR has been successfully added to your 
